A cancer treatment called tamoxifen, which previously showed promise in preclinical studies for the treatment of amyotrophic lateral sclerosis (ALS), provides only modest and short-lasting benefits to patients with the disease, a small Phase 1/2 clinical trial has found. According to the study’s researchers, larger studies and longer…
News
Treatment of people whose symptoms are suggestive of amyotrophic lateral sclerosis (ALS) but likely linked to a retrovirus called human T-cell lymphotropic virus type I (HTLV-I) should focus on alleviating symptoms and lowering the viral load, a case report highlights. The report, “Human T-cell Lymphotropic Virus…
The teeth of people with amyotrophic lateral sclerosis (ALS) show their bodies metabolize metals — from chromium to zinc — in abnormal ways starting in infancy, and these changes predispose them to ALS disease as adults. The study, which looked at how metal uptake early in life can affect…
The pivotal Phase 3 clinical trial testing BrainStorm Cell Therapeutic’s cell-based therapy NurOwn in amyotrophic lateral sclerosis (ALS) patients continues with only occasional scheduling changes to treatment due to the COVID-19 pandemic. Patient dosing is expected to be complete by July, the company announced. “BrainStorm made…
Statins, often prescribed to lower cholesterol levels, are not associated with poorer overall survival in people with amyotrophic lateral sclerosis (ALS) and should not be discontinued on that basis, a German study has found. The study, “Statins, diabetes mellitus, and prognosis of Amyotrophic…
Two bills making their way through Congress are intended to improve access to medical therapies for those most in need, and in particular, those with amyotrophic lateral sclerosis (ALS). Sen. Mike Braun, R-Ind., announced his plan to introduce a bill to hasten the regulatory process for making promising therapies…
The COVID-19 pandemic has imposed new challenges on diagnosing, monitoring, and caring for people with amyotrophic lateral sclerosis (ALS), from the absence of in-person visits to a lack of available equipment at hospitals. But the expansion of telemedicine may be a way to overcome these challenges, and allow…
For people with amyotrophic lateral sclerosis (ALS) currently on non-invasive ventilation, modifications to existing equipment may help to minimize risk of an infection for both them and their caregivers during the COVID-19 pandemic. The equipment adaptations were discussed in a letter to the editor, “Modification…
While the ongoing COVID-19 pandemic won’t have much of an impact on cash available for new biotech startups, it has begun to cause delays in the development of gene therapies to treat a variety of rare diseases. That’s the consensus of industry experts who spoke in a May 26 webinar…
The Phase 2 clinical trial investigating Clene Nanomedicine‘s CNM-Au8 as a potentially disease-modifying therapy for people with amyotrophic lateral sclerosis (ALS) has enrolled more than half of its participants ahead of schedule. RESCUE-ALS (NCT04098406) dosed its first participant in January,…
Recent Posts
- ‘Early birds’ have significantly lower ALS risk than ‘night owls’: Study
- As my late husband’s ALS progressed, we kept our bucket list simple
- Tossing and turning over fears this ALS journey has come to its end
- Experimental ALS therapy QRL-201 shows potential to slow disease decline
- Worried about an inability to multitask? Here’s what helped me.